CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time.

Tuesday, March 25th @ 8:30am ET
Domestic:   1-844-481-2557
International:   1-412-317-0561
Conference ID:   10197392
Webcast:   Webcast Link
     

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Staff

Recent Posts

Beyond Medical Technologies Reports Robust H1 2025 Progress, Sets Stage for Republic Technologies

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…

1 hour ago

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial

Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

1 hour ago

Avio Health Launches World’s First Functional Medicine LLM for Emagene Life, Transforming Personalized Healthcare

KUALA LUMPUR, Malaysia, June 27, 2025 /PRNewswire/ -- Avio Health, a deep-tech company dedicated to advancing healthcare through data analytics and machine learning, today announced…

4 hours ago

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that…

4 hours ago

Vinamilk Showcases Science-Driven Innovation and Wins Prestigious Awards at Global Dairy Congress 2025

AMSTERDAM, June 26, 2025 /PRNewswire/ -- Vinamilk, Vietnam's leading dairy company, presented its science-driven innovation…

10 hours ago